Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …

Abstract Background Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was
designed to have high potency and selectivity. Methods In a phase 1 study, we evaluated …

Lactylation is a lactate-induced post-translational modification best known for its roles in
epigenetic regulation. Herein, we demonstrate that MRE11, a crucial homologous …

In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …

In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like
(APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven …

Cancer relapse after chemotherapy remains a main cause of cancer-related death. Although
the relapse is thought to result from the propagation of resident cancer stem cells, a lack of …

Abstract KRAS G12C mutation is prevalent in~ 4% of colorectal cancer (CRC) and is
associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest …